Atacama Labs develops free flowing API granules
Offers PDG dry granulation as an alternative to wet granulation
Atacama Labs of Finland can provide free flowing granules of most any API with its proprietary pneumatic dry granulation (PDG) technology.
The Helsinki-based company says the PDG granulate offers a host of advantages compared with other granulates: it is flowable, compactible and improves disintegration and dissolution. Furthermore, the tablets can be furnished with a high drug load (70–95%), decreasing tablet size to improve patient compliance and making it optimal for fix combinations.
The technological advantages not only help in galenic development, but also in the later industrial production process, the company says. Significant cost reduction of up to 30%, a simple three-step process with continuous production and a high input/output ratio are also hallmarks of Atacama Labs' production method. Scale-up from lab scale is no longer considered to be an issue.
‘With our PDG process we are able to provide a simple, cost-effective and highly reliable production method, which also facilitates new pharmaceutical developments and helps to overcome existing galenic development hurdles,’ said Steffen Mittwich, chief executive of Atacama Labs.
New scientific study results regarding difficult-to-handle substances such as Paracetamol, Metformin, microcristalline cellulose and Ibuprofen are proving that these products can be transformed via dry granulation into freely flowing granulate with excellent compactibility properties, the firm says. The resulting tablets show satisfactory hardness and friability profiles with no capping and excellent disintegration and dissolution data.
Atacama Labs says its PDG technology improves life cycle management options, providing new product and production possibilities to pharmaceutical companies and oral dosage forms with high drug load in optimal quality.
